Related Research Articles
Chandler Park is an American physician, medical journalist, and clinical researcher. In June 2021, his cancer research was published in prominent medical journals including the New England Journal of Medicine and Journal of Clinical Oncology. Park also contributes regularly as an expert physician for popular newspapers and magazines such as Newsweek, Reader's Digest, U.S. News & World Report, The Exponent-Telegram, College of St. Scholastica, and Medscape and writes medical news for Doximity. In 2020, Park was selected as the President of the Kentucky Society of Clinical Oncology. The Kentucky Society of Clinical Oncology is the state affiliate of American Society of Clinical Oncology, American Society of Hematology, and National Cancer Institute.
Emil J. Freireich was an American hematologist, oncologist, and cancer biologist. He was recognized as a pioneer in the treatment of cancer and use of chemotherapy and is often known as the father of modern leukemia therapy.
The Society for Immunotherapy of Cancer (SITC), previously known as the International Society for Biological Therapy of Cancer (iSBTc), is a professional society of scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving outcomes in patients with cancer by advancing the science and application of cancer immunotherapy. Currently, SITC has more than 2,400 members, representing 22 medical specialties from 42 countries around the world, who are engaged in the research and treatment of cancer.
Napoleone Ferrara, is an Italian-American molecular biologist who joined University of California, San Diego Moores Cancer Center in 2013 after a career in Northern California at the biotechnology giant Genentech, where he pioneered the development of new treatments for angiogenic diseases such as cancer, age-related macular degeneration (AMD), and diabetic retinopathy. At Genentech, he discovered VEGF—and made the first anti-VEGF antibody—which suppresses growth of a variety of tumors. These findings helped lead to development of the first clinically available angiogenesis inhibitor, bevacizumab (Avastin), which prevents the growth of new blood vessels into a solid tumor and which has become part of standard treatment for a variety of cancers. Ferrara's work led also to the development of ranibizumab (Lucentis), a drug that is highly effective at preventing vision loss in intraocular neovascular disorders.
Clara Derber Bloomfield, was an American physician and cancer researcher. Her work focused on the genetic changes that are present in certain types of blood cancers, and how those can be utilized to improve treatment for the affected patients.
Henry Thompson Lynch was an American physician noted for his discovery of familial susceptibility to certain kinds of cancer and his research into genetic links to cancer.
Waun Ki Hong was Professor of Medicine at The University of Texas MD Anderson Cancer Center, where he served as chairman of the Department of Thoracic/Head & Neck Medical Oncology from 1993 to 2005 and as head of the Division of Cancer Medicine from 2001 to 2014. He was also an American Cancer Society Professor and the Samsung Distinguished University Chair in Cancer Medicine emeritus.
Edith A. Pérez is a Puerto Rican hematologist-oncologist. She is the Serene M. and Frances C. Durling Professor of Medicine at the Mayo Clinic Alix School of Medicine.
Maurie Markman is a physician and the President of Medicine & Science, City of Hope National Medical Center Atlanta, Chicago and Phoenix. He was previously the President of Medicine and Science at Cancer Treatment Centers of America and the Vice President for Clinical Research at M.D. Anderson Cancer Center at the University of Texas. In 1992 he was appointed the first Director of the Taussig Cancer Center at the Cleveland Clinic, a position he held for 12 years. During that time he was also Professor of Medicine and the Chairman of the Department of Hematology/Oncology at the Cleveland Clinic. He has also held appointments on the faculty of Memorial Sloan Kettering Cancer Center in NYC and Moores Cancer Center at the University of California, San Diego. He was named a "Giant of Cancer Care" in 2018 by OncLive.
Walter "Wally" J. Curran, Jr. is an American radiation oncologist specializing in the treatment of malignant brain tumors and locally advanced lung cancer.
Daniel D. Von Hoff is the physician in chief and director of translational research at Translational Genomics Research Institute (TGen), and current Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute. He is also a professor of medicine at the Mayo Clinic and medical director of research as well as chief scientific officer at US Oncology. He is most notable for his work in targeted therapies for the treatment of cancer. He led the development of gemcitabine, and has several drugs in development.
Bruce Allan Chabner is a professor of medicine at Harvard Medical School and Director of Clinical Research at the MGH Cancer Center at Massachusetts General Hospital. His research focuses on anti-folate drugs for the treatment of cancer.
The Rebecca and John Moores Cancer Center is the region's only NCI-designated Cancer Center in La Jolla, California, part of UC San Diego Health and affiliated with the University of California San Diego. It is supported, in part, by the National Cancer Institute.
Joseph Rocco Bertino was a researcher in the cancer pharmacology program at Rutgers Cancer Institute of New Jersey and professor of medicine and pharmacology at the Robert Wood Johnson Medical School in New Jersey. His research is focused on the treatment of lymphoma.
Judy Ellen Garber is the director of the Center for Cancer Genetics and Prevention at the Dana–Farber Cancer Institute and a professor of medicine at Harvard Medical School. Garber previously served as president of the American Association for Cancer Research.
Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.
Everett E. Vokes is an American oncologist. He is the John E. Ultmann Professor, chair of the Department of Medicine, and physician-in-chief at the University of Chicago Medical Center. In this role, he pioneered the combination radiation and chemotherapy as first-line treatment for head and neck cancer.
Stephanie Lynn Schutt Graff is an American breast medical oncologist. She is the Director of Breast Oncology at the Lifespan Cancer Institute and an Assistant Professor of Medicine at Alpert Medical School. Previously she was the Director of both the Breast Program and Clinical Research at Sarah Cannon Research Institute at HCA Midwest Health at Sarah Cannon Research Institute and Associate Director of the Breast Cancer Research Program at Sarah Cannon Research Institute.
Leonidas C. Platanias is a Greek-American oncologist. He is the director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Jesse, Sara, Andrew, Abigail, Benjamin and Elizabeth Lurie Professor of Oncology. He is internationally known for his research focused on cytokine signaling pathways in cancer cells, and for his contributions in developing therapies that target those pathways.
Tara Olive Henderson is an American pediatric oncologist. As the Arthur and Marian Edelstein Professor in the Department of Pediatrics, she is also the Director of the Childhood Cancer Survivor Center, Director of Survivorship at the University of Chicago Comprehensive Cancer Center, and chief of Pediatric Hematology and Oncology at the University of Chicago.
References
- ↑ "Scott M. Lippman, MD, Named New Director of UC San Diego Moores Cancer Center - The ASCO Post". www.ascopost.com.
- ↑ Yumpu.com. "Scott M. Lippman, M.D.: Short CV".
- ↑ "Scott M. Lippman, MD - Cancer - UC San Diego Health". doctors.ucsd.edu.
- 1 2 "Scott M. Lippman, MD, FASCO".
- ↑ "Director Scott M. Lippman, Director - Cancer Research - UC San Diego Health Sciences - Moores Cancer Center". UC San Diego Health Sciences.
- ↑ Lippman, Dr. Scott. "FRONTLINE CANCER: Son's cancer diagnosis brings home doctor's mission to find a cure".